Logo image of ALEMS.BR

EUROPEAN MEDICAL SOLUTIONS S (ALEMS.BR) Stock Fundamental Analysis

EBR:ALEMS - Euronext Brussels - BE0974497290 - Common Stock - Currency: EUR

6.42  +0.4 (+6.63%)

Fundamental Rating

1

Overall ALEMS gets a fundamental rating of 1 out of 10. We evaluated ALEMS against 73 industry peers in the Biotechnology industry. ALEMS has a bad profitability rating. Also its financial health evaluation is rather negative. ALEMS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year ALEMS has reported negative net income.
ALEMS had a positive operating cash flow in the past year.
ALEMS had negative earnings in each of the past 5 years.
In multiple years ALEMS reported negative operating cash flow during the last 5 years.
ALEMS.BR Yearly Net Income VS EBIT VS OCF VS FCFALEMS.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

The Return On Assets of ALEMS (-2.37%) is better than 70.83% of its industry peers.
Looking at the Return On Equity, with a value of -10.55%, ALEMS is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
ROA -2.37%
ROE -10.55%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALEMS.BR Yearly ROA, ROE, ROICALEMS.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200 -400 -600 -800

1.3 Margins

ALEMS has a Gross Margin of 17.08%. This is comparable to the rest of the industry: ALEMS outperforms 48.61% of its industry peers.
ALEMS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 17.08%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALEMS.BR Yearly Profit, Operating, Gross MarginsALEMS.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10

More info and screens

1

2. Health

2.1 Basic Checks

ALEMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for ALEMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALEMS.BR Yearly Shares OutstandingALEMS.BR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 500M 1B
ALEMS.BR Yearly Total Debt VS Total AssetsALEMS.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -1.32, we must say that ALEMS is in the distress zone and has some risk of bankruptcy.
ALEMS has a Altman-Z score (-1.32) which is in line with its industry peers.
A Debt/Equity ratio of 1.41 is on the high side and indicates that ALEMS has dependencies on debt financing.
The Debt to Equity ratio of ALEMS (1.41) is worse than 63.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF N/A
Altman-Z -1.32
ROIC/WACCN/A
WACC7.54%
ALEMS.BR Yearly LT Debt VS Equity VS FCFALEMS.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 5M -5M 10M -10M

2.3 Liquidity

ALEMS has a Current Ratio of 1.46. This is a normal value and indicates that ALEMS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.46, ALEMS is doing worse than 63.89% of the companies in the same industry.
ALEMS has a Quick Ratio of 1.46. This is a bad value and indicates that ALEMS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of ALEMS (0.85) is worse than 70.83% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 0.85
ALEMS.BR Yearly Current Assets VS Current LiabilitesALEMS.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M

More info and screens

1

3. Growth

3.1 Past

ALEMS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -33.33%.
The Revenue has grown by 9.86% in the past year. This is quite good.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
Revenue 1Y (TTM)9.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.07%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALEMS.BR Yearly Revenue VS EstimatesALEMS.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
ALEMS.BR Yearly EPS VS EstimatesALEMS.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
ALEMS.BR Price Earnings VS Forward Price EarningsALEMS.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALEMS indicates a somewhat cheap valuation: ALEMS is cheaper than 76.39% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.3
ALEMS.BR Per share dataALEMS.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALEMS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROPEAN MEDICAL SOLUTIONS S

EBR:ALEMS (3/7/2025, 7:00:00 PM)

6.42

+0.4 (+6.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17 2025-02-17
Earnings (Next)04-16 2025-04-16
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap27.16M
Analysts34.29
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.65
P/FCF N/A
P/OCF 43.66
P/B 2.67
P/tB 18.86
EV/EBITDA 27.3
EPS(TTM)0
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)0.15
OCFY2.29%
SpS9.84
BVpS2.4
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.37%
ROE -10.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 17.08%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 1.41
Debt/FCF N/A
Debt/EBITDA 10.47
Cap/Depr 160.58%
Cap/Sales 7.5%
Interest Coverage N/A
Cash Conversion 45.34%
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 0.85
Altman-Z -1.32
F-Score4
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)88.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.97%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-60%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)9.86%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.07%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.36%
OCF growth 3YN/A
OCF growth 5YN/A